<DOC>
	<DOCNO>NCT01250210</DOCNO>
	<brief_summary>The primary objective evaluate adequacy ovulation suppression , cycle control , safety three transdermal contraceptive delivery system ( TCDSs ) contain 2 different dos levonorgestrel ( LNG ) 3 different dos ethinyl estradiol ( EE ) 3 consecutive cycle administration treatment .</brief_summary>
	<brief_title>Evaluation Pharmacodynamic Effects Ovulation Suppression Cycle Control Three Agile Contraceptive Patches Containing Different Doses Ethinyl Estradiol ( EE ) During Three Cycles Administration</brief_title>
	<detailed_description />
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>1 . Healthy adult woman , age 1845 . 2 . Cycles usual duration 21 35 day individual variation +/ 3 day . 3 . Normotensive ( blood pressure &lt; 140/90 mm Hg rest ) screen randomization visit ( Visits 1 2 ) . 4 . Willing use nonhormonal method contraception entire duration study , 5 . Have already undergone previous bilateral tubal ligation OR vasectomize partner OR risk pregnancy . 6 . Willing refrain excessive use alcohol entire duration study . 7 . Willing give inform consent participate study . 1 . History significant medical illness seizure . 2 . Positive hepatitis B C antibody positive human immunodeficiency virus ( HIV ) antibody . 3 . Known suspected pregnancy . 4 . A recent abnormal cervical smear lowgrade squamous intraepithelial lesion ( SIL ) high Bethesda System resolve treat . 5 . Any disorder contraindicates use contraceptive steroid i.e. , history heart attack stroke , blood clot legs , lung eye , history blood clot deep vein legs , know suspect breast cancer , hepatitis yellowing white eye skin ( jaundice ) pregnancy previous use hormonal contraceptive , headache neurological symptom , disease heart valves complication . 6 . Uncontrolled thyroid disorder . 7 . History exist thromboembolic disorder , vascular disease , cerebral vascular , coronary artery disease . 8 . Undiagnosed abnormal genital bleeding . 9 . Known suspect breast carcinoma , endometrial carcinoma , estrogendependent neoplasia . 10 . History presence dermal hypersensitivity response topical application . 11 . Use injectable hormonal contraceptive ( e.g . DepoProvera® ) within 6 month prior Day 1 . 12 . Use contraceptive implant ( e.g . Implanon® Jadelle® ) hormonemedicated intrauterine device within 2 month ( 60 day ) prior Day 1 . 13 . Use OCs sex steroid hormone within 60 day prior Day 1 . 14 . Women breastfeed within 2 month stop breastfeeding . 15 . Status postpartum postabortion within period 2 month prior Day 1 . 16 . Chronic use medication might interfere metabolism hormone contraceptive ( e.g. , rifampin , barbiturate , phenytoin , primidone , topiramate , carbamazepine , phenylbutazone , ritonavir , modafinil , St John 's Wort etc . ) use within past 3 month prior Day 1 . 17 . Administration investigational drug within 30 day prior Day 1 . 18 . A history ( within prior 12 month ) drug alcohol abuse . 19 . Women smoke 45 cigarette daily . 20 . History skin sensitivity adhesive . 21 . Use overthecounter medication herbal might interfere metabolism hormone contraceptive within 3 day prior wear first patch .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>contraception</keyword>
	<keyword>pregnancy prevention</keyword>
</DOC>